Figure 1: Superiority of nivolumab-1/ipilimumab-3 for overall survival in patients with recurrent SCLC, as compared to nivolumab-3/ipilimumab-1 and nivolumab monotherapy
30.06.2016 | Chemotherapie | Online-Artikel
30.06.2016 | Chemotherapie | Online-Artikel
Figure 1: Superiority of nivolumab-1/ipilimumab-3 for overall survival in patients with recurrent SCLC, as compared to nivolumab-3/ipilimumab-1 and nivolumab monotherapy